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Background: Advances in childhood cancer treatment over the past decades have significantly improved survival,
resulting in a rapidly growing group of survivors. However, both chemo- and radiotherapy may adversely affect
reproductive function. This paper describes the design and encountered methodological challenges of a
nationwide study in the Netherlands investigating the effects of treatment on reproductive function, ovarian
reserve, premature menopause and pregnancy outcomes in female childhood cancer survivors (CCS), the DCOG
LATER-VEVO study.
Methods: The study is a retrospective cohort study consisting of two parts: a questionnaire assessing medical,
menstrual, and obstetric history, and a clinical assessment evaluating ovarian and uterine function by hormonal
analyses and transvaginal ultrasound measurements. The eligible study population consists of adult female 5-year
survivors of childhood cancer treated in the Netherlands, whereas the control group consists of age-matched
sisters of the participating CCS. To date, study invitations have been sent to 1611 CCS and 429 sister controls, of
which 1215 (75%) and 333 (78%) have responded so far. Of these responders, the majority consented to participate
in both parts of the study (53% vs. 65% for CCS and sister controls respectively). Several challenges were
encountered involving the study population: dealing with bias due to the differences in characteristics of several
types of (non-) participants and finding an adequately sized and well-matched control group. Moreover, the
challenges related to the data collection process included: differences in response rates between web-based and
paper-based questionnaires, validity of self-reported outcomes, interpretation of clinical measurements of women
using hormonal contraceptives, and inter- and intra-observer variation of the ultrasound measurements.
Discussion: The DCOG LATER-VEVO study will provide valuable information about the reproductive potential of
paediatric cancer patients as well as long-term survivors of childhood cancer. Other investigators planning to
conduct large cohort studies on late effects may encounter similar challenges as those encountered during this
study. The solutions to these challenges described in this paper may be useful to these investigators.
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Cancer treatment can have detrimental effects on repro-
ductive function. In women, there is evidence that both
chemo- and radiotherapy can adversely affect ovarian
function, ovarian reserve and uterine function, clinically
leading to sub- or infertility, premature menopause and/
or adverse pregnancy outcomes [1-9]. However, previous
studies addressing the late effects of cancer treatment on
female fertility have several limitations. Clinical ovarian
reserve tests are often lacking (i.e. data from question-
naires only) [1-6,10-19], and study populations are often
small and heterogeneous [20-27]. Therefore, we designed
the DCOG LATER-VEVO study (Dutch Childhood On-
cology Group - Long term Effects after Childhood
Cancer/ Fertility, Ovarian reserve and Premature Meno-
pause (Dutch acronym)) in the Netherlands. Patient in-
clusion started in 2008.
The study aims to evaluate the effects of cancer treat-
ment on the reproductive system of female childhood
cancer survivors (CCS) in the Netherlands and their risk
of premature menopause. The effects of treatment in
general will be assessed, as well as the effects of different
treatment modalities, doses of drugs, radiation sites and
doses, and age at time of treatment. The study includes
a questionnaire survey and a full panel of ovarian func-
tion and reserve tests. The DCOG LATER-VEVO study
is the first nationwide childhood cancer survivor study
in the Netherlands and during the study period several
methodological challenges were encountered.
In this paper the key methodological and practical
challenges are discussed as well as the way they were
addressed. Other investigators planning to conduct large
nationwide cohort studies among childhood cancer sur-
vivors will benefit from this information when faced with
similar challenges.Patients and methods
Design and study population
The DCOG LATER-VEVO study is a multi-center retro-
spective cohort study including female 5-year survivors
of childhood cancer. The study consists of three parts: a
questionnaire survey, the provision of a blood sample,
and a transvaginal ultrasound measurement of the re-
productive organs, the latter two requiring a visit to the
outpatient clinic. Approval was obtained from the rele-
vant medical ethics committees and written informed
consent was obtained from all participants.
Eligible cohort members are selected from a cohort of
patients treated for childhood cancer between 1963 and
2002 at one of the seven Dutch paediatric oncology -
and stem cell transplant centers, collectively known as
the Dutch Childhood Oncology Group - Longterm
Effects after Childhood Cancer (DCOG LATER). Thisgroup has developed a nationwide electronic database
including patient and treatment details of all CCS in the
Netherlands (DCOG LATER database). The study popu-
lation consists of those female CCS who were treated for
a malignancy or central nervous system tumour before
the age of 18, who survived for at least 5 years after
diagnosis, and who were at least 18 years at study entry
(n = 2331). The exclusion criteria for participation in the
study include: deceased before the start of the study
(n = 271), living abroad or unknown address (n = 75), not
being able to speak or read Dutch (n = 1), having severe
mental sequelae (n = 40), being treated for second malig-
nant neoplasm at the time of study inclusion (n = 34),
and previously having indicated not willing to participate
in research (n = 13). Thus, a total of 1897 female child-
hood cancer survivors are eligible for participation in
the DCOG LATER-VEVO study.
Sisters of participating CCS who have never been diag-
nosed with cancer, who are able to read and speak
Dutch, and who are 18 years or older, are asked to par-
ticipate in the control group of the study. For this pur-
pose participating CCS are asked to contact all sisters
meeting the inclusion criteria and to provide their con-
tact information to the investigators. If a female survivor
chooses to not register one or more available sisters, the
reason is enquired about.
Approach of study participants and data collection
All eligible women receive a mailed package containing
extensive study information, an informed consent and
refusal form, and a questionnaire. They are asked to
complete the questionnaire and return it with a signed
informed consent form. Furthermore, they are asked to
indicate on the informed consent form in which parts
of the study they are willing to participate. In case of no
response within 3 weeks, postal reminders are sent.
When again after 3 weeks no response has been
received, the women are contacted by telephone.
Women who are not willing to participate in either part
of the study are asked to complete a refusal form on
which they can indicate the reason for not wanting to
participate. These non-participants are asked to com-
plete a brief questionnaire regarding parity, wish to have
children, subfertility, subfertility treatment, and educa-
tional level in order to adjust for possible bias. The enve-
lope containing the study information package is sealed
and put in another envelop, together with a cover letter
in which the study is explained very briefly. This is done
in order to give the survivors the opportunity to choose
whether or not they want to be confronted with the
extensive study information. If not, they can send the
unopened package return to sender. Figure 1 depicts
the various response categories that apply to the DCOG
LATER-VEVO study.
Figure 1 Response flow chart. The following categories and definitions are used to classify participants and non-participants in the DCOG
LATER-VEVO study: 1) “eligible subjects” are individuals registered in the DCOG LATER database who were confirmed as meeting the study
eligibility criteria; 2) “participants” are those who consented to participate; 3) “non-participants” are individuals who declined participation verbally
or in writing, who returned the envelope with study information unopened or who, at first indicated they were willing to participate but
ultimately did not do so; 4) subjects are considered “lost to follow-up” if they were not located after intensive tracing efforts; and 5) individuals
are classified as “pending” when they are actively being traced and recruited to participate.
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same, with the exception of data related to the anti-cancer
treatment in the past. For both survivors and siblings in-
formation on reproductive and medical history is obtained
by a questionnaire which is available either as hard copy
or online. This questionnaire is an adaptation of a well-
tested questionnaire used by the Department of Epidemi-
ology of the Netherlands Cancer Institute in a large-scale
Dutch cohort study of long-term effects of ovarian
stimulation for in vitro fertilization [28,29]. It addresses
the following issues: socio-demographic characteristics,
menstrual history, desire to have children, reproductive
history, pregnancy information, pregnancy outcomes,
details of offspring, menopausal symptoms and meno-
pause, use and duration of use of exogenous hormones,
use and duration of use of fertility drugs and assisted re-
productive techniques, family history of cancer and sub-/
infertility, co-morbidities, and life style behaviour.In order to assess reproductive function and ovarian
reserve a blood sample is drawn and a transvaginal ultra-
sound of the reproductive organs is performed. From the
blood sample, FSH, LH, estradiol, inhibin-B, prolactin,
and AMH concentrations are determined as well as the
FSH receptor genotype. The ultrasound measurements,
which assess the number of antral follicles in both ovar-
ies as well as the length and width of the ovaries and the
uterus, are performed by specifically trained personnel
using a HD11 XE ultrasound system with a transvaginal
probe which can perform three-dimensional (3D)
imaging (EnVisor HD, Philips Medical Systems, Eindho-
ven, the Netherlands). First, a 2D ultrasound assessment
of the pelvis is performed after which an automated
mechanical sweep produces the 3D data. An ultrasound
measurement is not performed when the participant
indicates in the questionnaire that she has not yet been
involved in sexual intercourse, unless she explicitly states
Table 1 Response and participation rates of childhood
cancer survivors and sister controls in the DCOG
LATER-VEVO study*
Survivors sister
controls
Invited 1611 429
Response received (responders) 1215 (75%) 333 (78%)
No response received (non-responders) 396 (25%) 96 (22%)
Responders
Participants
Questionnaire only 306 (19%) 96 (22%)
Questionnaire and blood sample 126 (8%) 43 (10%)
Questionnaire, blood sample and
transvaginal ultrasound
509 (32%) 174 (41%)
Non-participants 274 (17%) 20 (5%)
* Rates acquired as of March 1st 2012.
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sampling and ultrasound measurements require specific
timing. For both CCS and controls not using hormonal
contraceptives this timing is as follows: (1) on day 2–5 of
a natural menstrual cycle; (2) on any convenient moment
in case of amenorrhea (no menses > 6 months). In those
who are using hormonal contraceptives, alternative
methods of timing were used (see section “The value
of hormonal and ultrasound markers while using oral
contraceptives”).
Since January 2008, invitations have been sent to 1611
female CCS and 429 sister controls from all participating
centers and data collection is still ongoing. As of March
1st 2012, 1215 CCS and 333 sister controls have
responded, whereas from the remaining 396 survivors
and 96 controls no response has been received to date.
Table 1 describes the response and participation rates of
CCS and controls as of March 1st 2012.
Challenges
The challenges encountered during the study can be
divided into two categories: challenges related to the
study population and challenges related to the data col-
lection procedures.
Study population
Bias due to different characteristics of the women in
the various response groups
Eligible study subjects can either respond (responders)
or not respond to the study invitation (non-responders).
The responders either decide to participate (participants)
or not to participate in the study (non-participants). When
they decide to participate they can subsequently choose
to take part in one, two or all three parts of the study.
In total, three groups of participants are distinguished:1. questionnaire only; 2. questionnaire and blood sample;
3. questionnaire, blood sample and transvaginal ultra-
sound. The responders may not be comparable to the
non-responders and the same is true for non-participants
versus participants. In addition, subjects who choose to
complete the questionnaire only may not be comparable
to those who also participate in the clinical assessment.
This may potentially lead to selection bias, which may
influence the validity of the study results. Therefore, it is
important to identify potential differences between the
various response groups in order to be able to control for
selection bias during the data analyses of the DCOG
LATER-VEVO study.
In order to identify the presence and direction of
possible selection bias interim data analyses were per-
formed, in which differences between the characteristics
of responders and non-responders were compared.
Results showed that the age at study invitation (28.8 vs.
28.2 years), age at diagnosis (6.96 vs. 7.06 years) and
time since treatment (7998 vs. 7658 days) were not dif-
ferent between responders and non-responders. In
addition, differences between the characteristics of parti-
cipants and non-participants were compared. Results
showed that the non-participating CCS (n = 274) did not
significantly differ from the participating CCS regarding
current age (p = 0.09). In addition, there were no signifi-
cant differences in age at diagnosis or in time since diag-
nosis (p = 0.23 and p= 0.24, respectively). Of the 274
non-participants, 17% (n = 46) were willing to complete
the brief non-participant questionnaire. Data from this
questionnaire showed no significant differences with
regard to educational level, although the proportion of
women with a high educational level in the participants
group was substantially higher compared to the non-
participants group (39.9% vs. 26.1%, p = 0.09). Moreover,
a larger proportion of the non-participants reported to
already have offspring in comparison with participants.
However, this difference was not significant either
(46.3% vs. 33.9%, p = 0.10). Nevertheless, this may sug-
gest that women with proven fertility may be less likely
to participate in the study than those who have not given
birth (yet). This implies that caution should be taken
when interpreting the results of the DCOG LATER-
VEVO study since an overestimation of the adverse
effects of the cancer treatment on reproductive out-
comes (i.e. actual fertility) might be introduced. We
realize, however, that the number of women completing
the non-participant questionnaire was rather low. As
a consequence, this group of women may not be fully
representative of the total group of non-participants.
However, the non-participants that did and those
who did not complete the non-participant questionnaire
appeared not to significantly differ regarding current
age, age at diagnosis, and time since diagnosis.
Table 2 Comparison of several characteristics between two different groups of participants
Variable Participants P value
Participating in questionnaire
part only (n = 306)
Participating in questionnaire
and clinical part (n = 635)
Age (years) 30 (18–52) 27 (18–56) <0.001
Age at diagnosis (years) 6 (0–16) 6 (0–17) NS
Time since diagnosis (days) 8280.5 (2563–15423) 7418 (2068–14612) 0.001
High education (n/N) (%)* 103/300 (34.3) 267/619 (43.1) 0.002
In committed relationship (n/N) (%)* 217/304 (71.4) 431/633 (68.1) NS
Has had intercourse (n/N) (%)* 248/303 (81.8) 555/631 (88.0) 0.01
Has offspring (n/N) (%)* 146/304 (48.0) 183/633 (28.9) <0.001
Has previously consulted a gynaecologist
for fertility problems (n/N) (%)*
46/289 (15.9) 72/621 (11.6) NS
Data presented as median (range) unless indicated otherwise. NS = not significant. * Total N does not correspond with the number mentioned in the heading of the
table because of missing data.
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ticipating groups, we evaluated the differences in charac-
teristics between those participating in the questionnaire
part only and those participating in both the question-
naire and the clinical part (blood and/or ultrasound) of
the study (Table 2). It appeared that women who com-
pleted the questionnaire only were older, had a longer
follow-up time since diagnosis, were less likely to be
highly educated, were more likely to have had inter-
course and to have offspring than women who also
agreed to participate in the clinical part.
Participants who ultimately did not show up for outpatient
clinic visit
If participants decide to provide a blood sample and/or
undergo a transvaginal ultrasound, they are asked to
contact the research staff on a specific day of their men-
strual cycle in order to plan the clinical assessment at
the outpatient clinic. However, we experienced that
some participants who initially consented to a clinical
assessment did not (yet) follow-up on their decision
6 months after their written consent (n = 90) . Twenty-
seven women (30%) have expressed a reason (pregnancy,
breastfeeding, illness or disability, and personal or family
responsibilities) while the remaining 63 have not yet
contacted the research staff, even after several remin-
ders. Ultimately, these women will be classified as non-
participants to the clinical part of the study.
Finding an adequately sized and well-matched
control group
Sisters of participating CCS are invited as controls, since
they have the same genetic and socio-economic back-
ground (which might influence fertility and other out-
comes). However, the inclusion of only sisters in the
control group has shown to result in insufficientnumbers compared to the number of CCS (941 versus
313, see also Table 1). The reason is two-fold: not all
participating CCS have an eligible sister aged 18 years or
older and not all CCS with eligible sisters gave permis-
sion to contact their sisters for the control group. For
the DCOG LATER-VEVO study this may ultimately re-
sult in insufficient power for certain subgroup analyses.
Moreover, not all research questions of the study require
a control group that is genetically and/or socioeconomi-
cally comparable to the survivor group. Therefore, it
was decided to expand the control group by including
women from the general population as well.
For this purpose, general practitioners of the partici-
pating CCS are asked to randomly select and invite sub-
jects from their female patient population. For logistical
reasons, we selected general practitioners practices
located in the area surrounding the coordinating center.
In order to ensure a comparable age distribution
between CCS and controls, these general practitioners
are asked to select women within a specified age range
of five years (so-called “GP controls”). For these women,
the same inclusion criteria apply as for the sister con-
trols: never to have been diagnosed with cancer, able to
read and speak Dutch, and 18 years or older. This
method of approach resulted in 1184 women who were
invited to participate in the DCOG LATER-VEVO study
as controls. So far, 935 (79%) have responded and 429
women have consented to participate, 308 of whom in
the clinical part of the study.
Within the group of eligible controls recruited via the
general practitioners, we conducted a non-responder
analysis. A random sample (n = 200) was drawn from the
GP controls who did not respond to the study invitation.
From these women the following variables were col-
lected from the medical records at the general practi-
tioner’s office: age, having offspring, maternal age at first
Table 3 Differences between sister controls and controls recruited through the general practitioner (GP controls)
sister controls
(n = 313)
GP controls
(n = 430)
P value
Age 30 (18–58) 34 (18–54) <0.001
High education (n/N) (%) 158/308 (51.3) 293/428 (68.5) <0.001
Is in committed relationship (n/N) (%) 249/311 (80.1) 341/428 (79.7) NS
Has had intercourse (n/N) (%) 288/312 (92.3) 407/426 (95.5) NS
Has offspring (n/N) (%) 140/313 (44.7) 201/429 (46.9) NS
Has previously consulted a gynaecologist
for fertility problems (n/N) (%)
29/301 (9.6) 44/411 (10.7) NS
Data presented as median (range) unless indicated otherwise. NS = not significant.
Table 4 Factors associated with the probability of
completing the web-based version of the questionnaire:
results of logistic regression*
OR (95% CI)
Age 1.08 (1.02-1.15)
Educational level (ref. group: High level)
Medium 0.65 (0.28-1.53)
Low 0.06 (0.01-0.52)
Employment status (ref. group: Employed)
Student 3.25 (1.00-10.56)
Unemployed 0.35 (0.10-1.29)
Randomization group
(ref. group: Mixed invitation group)
2.85 (1.31-6.21)
OR, odds ratio; CI, confidence interval.
* Derived from Van den Berg MH et al. Using web-based and paper-based
questionnaires for collecting data on fertility issues among female cancer
survivors: differences in response characteristics. J Med Internet Res.
2011 Sep 29;13(3):e76.
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cologists. These data, which were made anonymous for
privacy reasons, were compared with data of a random
sample of GP controls who did respond to the study in-
vitation (n = 194). Preliminary results show no significant
differences between the two groups with respect to the
before-mentioned variables. This suggests that the de-
gree of selective participation within the GP control
group is low.
We also evaluated whether sister controls differed
from the GP controls on several basic characteristics
(Table 3). Results show that GP controls were more
likely to have a high educational level. In addition, these
women were older than sister controls. There were no
significant differences between siblings and GP controls
with regard to relationships, offspring or fertility issues.
Data collection
Differences in response between web-based and paper-
based questionnaires
Web-based questionnaires have several advantages over
paper-based questionnaires. They are less time-consum-
ing, less costly, and the data of the respondents are
already available in an electronic format, leading to less
input errors [30-32]. At the time the DCOG LATER-
VEVO study was set up, no literature was available con-
cerning the differences in response rates of CCS to a
web-based or a hard copy paper questionnaire, when
they are offered both types of questionnaire. Therefore,
we conducted a nested randomized study to evaluate
whether the use of either the web-based or hard copy
paper questionnaire resulted in differences in response
rates, type of response, and characteristics of the (non-)
responders. In this study, 277 eligible women were ran-
domly selected to receive either a mixed invitation
(a hard copy paper questionnaire together with the login
details for the web-based questionnaire) or a web-only
invitation (login details only). Women receiving the
web-only invitation were given the opportunity to apply
for a hard copy of the questionnaire by returning a form.
The results showed that although the overall responserates to both types of invitation were similar, adding a
paper version of a questionnaire to a web-only invitation
resulted in more respondents completing the hard copy
of the questionnaire. In addition, women who were
older, higher educated as well as those who were a stu-
dent, had a higher probability of completing the web-
based version of the questionnaire (Table 4) [33]. It was
decided that future invitations for the DCOG LATER-
VEVO study should include both a hard copy of the
questionnaire and the login details for completing the
web-based questionnaire.
Validity of self-reported outcomes
Previous studies on fertility and pregnancy outcomes in
CCS were often designed as large cohort studies in which
the outcomes of interest were obtained through interviews
or mailed questionnaires [4,13]. However, the reliability
and validity of self-reported data can be limited and one
should be aware of possible (non-) differential misclassifi-
cation bias. Several studies among healthy women have
been performed assessing the accuracy and validity of self-
report for pregnancy outcomes. Data from these studies
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ately reported, but time to pregnancy, reasons for subfer-
tility, and maternal and neonatal complications during
labour and delivery were reported with less accuracy [34-
36]. Since no literature was available assessing the validity
of self-reported pregnancy outcomes by CCS, we con-
ducted a validation study among our study participants
[37]. Women were eligible for the validation study when
they reported in the questionnaire to have had a child be-
tween 1/1/1985 and 31/12/2009. Reference data on preg-
nancies and pregnancy outcomes were abstracted from
the Netherlands Perinatal Registry (PRN). In this nation-
wide population-based registry pregnancy outcomes of
all births are registered by midwives, obstetricians and
paediatricians and data are available from 1985 to 2009.
Records of self-reported pregnancies were linked to the
PRN by using both the mother’s date of birth and the
child’s date of birth as linkage keys. At the time of the
validation study, 879 CCS and 287 controls had returned
the study questionnaire. In total, 589 pregnancies were
reported in 289 CCS compared to 293 pregnancies in
123 controls. Linkage to the PRN yielded 510 unique hits
(345 pregnancies in 186 CCS, and 186 pregnancies in 87
controls). A high intra-class correlation coefficient (ICC)
was found for birth weight (0.94 (95%CI 0.91-0.96) and
0.87 (95%CI 0.83-0.90) for CCS and controls, respectively).
For gestational age, the ICC was 0.88 for CCS (95%CI
0.85-0.91), but only 0.49 for controls (95%CI 0.32-0.62).
The kappa value for method of conception was moderate
to good, but varied largely per method (0.56 for hormonal
stimulation to 1.0 for IUI). The kappa values for different
methods of delivery were good for CCS and controls (0.76
for spontaneous delivery to 0.92 for vacuum/forcipal ex-
traction). Kappa for pregnancy-induced hypertension was
0.59 for CCS and 0.61 for controls. Multilevel analyses
showed no differences in accuracy associated with time
since pregnancy or educational level.
The value of hormonal and ultrasound markers while using
oral contraceptives
The results of a pilot study conducted before the start of
the DCOG LATER-VEVO study showed that 55% of the
CCS used oral contraceptives. As it was anticipated that
the response rates to the study would be significantly
lower when the participants had to stop using oral contra-
ceptives to be eligible for our study, we conducted a study
to compare both hormonal and ultrasound markers of
ovarian reserve measured on day 7 of the pill free interval
and two subsequent natural cycles. Results showed that
FSH and inhibin B values decreased significantly when
contraception use was discontinued, whereas values of
AMH, AFC and ovarian volume increased significantly.
Thus, hormonal and ultrasound markers of ovarian func-
tion in oral contraceptive users measured at the end of thehormone-free interval do not fully represent subsequent
natural early follicular phase values. However, FSH, AMH
and AFC can be used to predict early follicular phase
values using calculated prediction equations [38].
The results of this study have led to the following proce-
dures regarding the timing of the clinical measurements of
the DCOG LATER-VEVO study. Women who are on oral
contraceptives or who use a combined contraceptive vagi-
nal ring are asked to refrain from using these and use other
methods of birth control (condoms were provided free of
charge), for at least two months prior to the outpatient
clinic visit. Depending on the menstrual pattern they de-
velop, these participants are invited according to the timing
schedule described above (see section “Approach of study
participants and data collection”) during the second natural
menstrual cycle. Women who do not wish to discontinue
the use of oral contraceptives or vaginal ring during the
study period are invited on day 7 of the pill-free or ring-
free period for the clinical measurements. Women who use
a hormone-containing intrauterine device (IUD) are asked
to monitor their basal body temperature (BBT) daily for at
least 4 weeks. The BBT chart is evaluated by an experi-
enced gynaecologist (CBL) to detect ovulation. Ovulation is
confirmed when the chart appeared to be biphasic
(temperature shift of at least 0.5 °C). The date of the assess-
ment for the study is then planned in the early-follicular
phase. A monophasic BBT chart was deemed anovulatory
and the measurements are planned at any convenient mo-
ment. Women using long-acting contraceptive injections
or women with a contraceptive implant are excluded from
the clinical part of the study.
Blinding and inter- and intra-observer variation of
ultrasound measurements
To assess ovarian function and ovarian reserve all study
participants who consent to this procedure undergo a
transvaginal ultrasound. This measurement is performed
in five centers across the Netherlands, making this exam-
ination as convenient and as timesaving for the participant
as possible. All centers are equipped with the same type of
3D ultrasound apparatus. It is not possible to blind ultra-
sonographers to the CCS status of the participants given
the fact that the participants themselves are evidently not
blinded to their status and often ask questions regarding
their prior cancer treatment during the clinical visit. How-
ever, the ultrasonographers do not have access to diagnos-
tic or treatment data prior to or during the procedure.
Moreover, the stored 3D files are made anonymous and
therefore, no prior knowledge regarding the diagnosis or
treatment is available to the investigator analysing the 3D
data. This will minimize observer bias.
3D ultrasound is capable of visualizing all three ortho-
gonal planes simultaneously. With the stored volumetric
data, imaging can be accurately evaluated offline.
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surements have high intra-observer and inter-observer
reliability [38-41], but some limitations were found in
the between-method reliability and the degree of agree-
ment when higher numbers of follicles were counted
[42]. However, these validation studies have all been per-
formed in healthy controls, or in women undergoing
IVF/ICSI treatment. The 2D and 3D techniques have
not been validated for women treated for childhood can-
cer in the past. Former treatment might have induced
changes to the reproductive organs, which might result
in changes in the intra- and inter-observer reliability of
both methods. Moreover, the between-method reliability
of real-time 2D images and stored 3D images acquired
from CCS has not been investigated so far. Therefore,
we are conducting an evaluation of the intra-observer,
the inter-observer, and the between-method reliability of
both the 2D and 3D ultrasound measurements of the
DCOG LATER-VEVO study.Discussion
This study on reproductive function, ovarian reserve,
and risk of premature menopause in female childhood
cancer survivors is the first large nationwide late effects
study in the Netherlands. Compared to previously con-
ducted studies on reproductive outcomes in CCS, this
DCOG LATER-VEVO study has several strengths.
First, the results of the study are not solely based on
self-reported data from questionnaires. Clinical data
on ovarian and uterine function are included as well,
which allow for a more objective evaluation of the actual
fertility status. The extensive set of data acquired in
this study will result in detailed knowledge regardingTable 5 Challenges and recommendations
Challenge
Study population Dealing with participation bias
• Responders and non-responders
• Participants and non-participants
• Different types of participants
• Participants lost to follow-up for the clinical assessm
Finding an adequately sized and well-matched contro
Data collection Validating instruments for data collectiontreatment-induced effects on the female reproductive
potential, particularly the effects of different types of
treatment, doses of drugs, radiation sites and doses, and
age at time of treatment.
Second, when data collection of the study is finalized,
the reproductive data of the CCS can be compared with
those of a large number of controls. For these controls
questionnaire as well as clinical data are available. The
size of the control group as well as the availability of
clinical data from these controls can be considered
unique study features within the field of late effect stud-
ies among CCS.
Third, the complete cohort of adult female child-
hood cancer survivors treated in one of seven Dutch
paediatric oncology centers is invited to participate in
the study, thereby minimizing the risk of selection
bias due to loss to follow-up. This is possible because
recently a database containing up-to-date patient and
treatment data of all Dutch 5-year CCS diagnosed be-
fore 2002 has been established. In addition, through
the Dutch system of municipal population registries,
which fully cover the Dutch population, individuals
can nearly always be traced, despite frequent moving.
Furthermore, inclusion of the complete cohort pro-
vides the advantage of a well-powered study in which
several subgroup analyses can reliably be performed.
Despite the above-mentioned strengths of the DCOG
LATER-VEVO study, we have also identified several
challenges in the design and conduct of the study. To
address these challenges, several recommendations
have been formulated (Table 5).
Our results have shown that there are no significant
differences between participants and non-participants
regarding socio-demographic data. Nevertheless, a trendRecommendations
• Keep non-response or loss to follow-up to a minimum
• Characterize non-responders or those lost to follow-up
• Control for extent and direction of bias in final data analysis
ent
l group
• In case the number of controls is insufficient: incorporate
other types of control subjects
• Choose types of controls that are representative of the
study population
• Characterize and control for differences between survivors
and controls
• Compare self-reported data with an more objective source,
such as medical records or registries
• Conduct reliability studies to account for inter- and intra-
observer variation
• If possible, use data collection instruments that allow for
one investigator to analyse collected data (observer bias)
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participant group, as well as lower offspring rates. Differ-
ences between participants and non-participants may
introduce participation bias. This type of bias can be
minimized when the number of subjects refusing to par-
ticipate is kept to a minimum. Moreover, it is important to
ask women who do not wish to participate to complete a
brief non-participants questionnaire in order to be able to
characterize this group. By the time data collection of
the DCOG LATER-VEVO study is completed, charac-
teristics of participants and non-participants will be
compared once again. By doing so, the extent and direc-
tion of participation bias can be established, which can
be taken into account when analyzing the data.
During the study period it became clear that a
group of participants, who initially consented to visit
the outpatient clinic for blood sampling and/or ultra-
sound measurement, ultimately did not do so. We are
making every effort to keep the number of these ‘no-
shows’ as low as possible since this selective non-
participation might add to selection bias. Indeed,
those who feel less inclined to visit the clinic might
differ from those who do [43]. At this time, the direc-
tion and the magnitude of this bias is difficult to pre-
dict. It might be the case that those who ultimately
do not visit the clinic may be more fertile and do not
see the need for the clinical measurements (anymore).
However, these women might also have obtained informa-
tion that they are infertile. It is therefore of paramount im-
portance that basic information regarding the main
outcomes of this study is also collected for the women
who ultimately did not show up for the clinical visit. For-
tunately, many of these women are seen periodically in
outpatient clinics throughout the country for late effects
follow-up screening. This enables us to retrieve informa-
tion regarding reproductive outcomes of these women
and to further investigate possible bias.
Two types of controls are included in the study, i.e.
sisters of participating CCS and women from the general
population recruited through general practitioners. For
our study, siblings form a better control group than a
random sample from the population, based on a munici-
pal registry sample, neighbourhood controls, or friends
and relatives. They share the same genetic and socio-
economic background as the CCS. Furthermore, siblings
may be more motivated to participate for altruistic rea-
sons, i.e. participating in the study for the sake of their
sister, whereas controls from a random sample in the
population might have other reasons to participate, for
example, fertility problems. This could also lead to selec-
tion bias, which could consequently influence our study
results. The strong recommendation to register all sisters,
and not to choose only one, may further reduce this form
of sampling bias.However, when including only sisters as controls, the
number of controls would be significantly lower than
the number of survivors. In order to attain sufficient
power for the planned statistical analyses, we chose to
also include women from the general population. By
using a ‘targeted’ invitation strategy we aimed to
minimize the risk of selection bias caused by selective
participation of, for example, women experiencing fertil-
ity problems. Several general practitioners were asked to
randomly select and invite women with a specific year of
birth from their patient population. In this way, bias due
to selective participation is expected to be less compared
to applying a broader invitation strategy, for example
by using advertisements in daily newspapers to recruit
controls. However, it is still probable that some form of
selection bias has occurred, since comparisons between
the sister controls and GP controls show that the latter
group is older and more likely to have a higher educa-
tional level.
In order to minimize the travelling time associated
with attending the outpatient clinic, only general practi-
tioners located close to the coordinating center (VU
University Medical Center Amsterdam) were approached
for the recruitment of controls. We realize that this
method may introduce additional bias, because of
regional differences, which can ultimately lead to select-
ive participation.
Another limitation of the study is the fact that CCS and
controls may differ regarding their ability to accurately re-
call information about past (medical) events, leading to
so-called recall or misclassification bias. CCS might better
recall their past medical history, because they are fre-
quently seen in outpatient clinics for follow-up, whereas
controls may have forgotten about less severe medical
problems they have encountered in the past. This might
lead to an overestimation of the risk of medical problems
in the survivor group. Furthermore, most CCS are aware
of the fact that their previous cancer treatment may have
had detrimental effects on their fertility. As a conse-
quence, they may report more accurately on several
fertility-related items since they have been (or still are)
more ‘focused’ on fertility-related events from the past.
There is no method available to correct for this type of
bias. Nevertheless, the use of objective measurements,
such as hormonal analyses and ultrasound examinations,
and the validation of self-reported data by comparing with
medical records or available registries may minimize the
influence of this type of bias.
In order to evaluate the validity of the several outcomes
in the study questionnaire, we conducted a study in
which self-reported data on pregnancies were compared
to data from a nationwide registry. Overall, self-reported
pregnancy outcomes of CCS indeed appeared to agree
better with the registry data than those of controls. This
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and a higher frequency of medical follow-up. Although
self-reported data regarding fertility and pregnancy by
CCS seem consistent with registry parameters, differen-
tial misclassification between CCS and controls may
occur and should be taken into account when interpret-
ing the data. In the near future, we also aim to validate
data on fertility issues and gynaecological disorders by
comparing the questionnaire data to the medical records.
Clinical measurements for the study were performed
at several locations throughout the Netherlands. In order
to rule out observer bias, all ultrasound data will be ana-
lysed by one investigator using stored 3D ultrasound
data. In addition, all endocrinological measurements will
be done in a single laboratory at the end of the study, as
it is not unlikely that changes in laboratory kits will
occur during the study period.
In conclusion, the results of this nationwide study will
provide valuable information for counselling female
childhood cancer patients and survivors regarding their
reproductive potential now and in the future. Other
investigators planning to conduct large nationwide
cohort studies on late effects may encounter similar
challenges as those encountered during this study. Our
experiences as well as the way we addressed these chal-
lenges will hopefully contribute to an optimal design and
conduct of future late effects studies.
Competing interests
The authors declare that they have no conflict of interest.
Authors’ contributions
Both AO and MHB wrote the manuscript and contributed equally. All authors
contributed to the design of the study and its coordination. AO and MHB
are responsible for study logistics, patient recruitment, and data collection.
EDB, CBL, FEL, and GJK are principal investigators. EVD was responsible for
writing the grant proposals for funding of the study. LCK, MMHE, WJT, JJL,
BV, and DB supported local patient recruitment and are clinically responsible
for, respectively, the Emma Children’s Hospital/Academic Medical Center, the
Sophia Children’s Hospital/Erasmus MC University Medical Center, the Beatrix
Children’s Hospital/University Medical Center Groningen, the Radboud
University Nijmegen Medical Center, the Wilhelmina’s Children’s Hospital/
University Medical Center Utrecht, the Willem-Alexander Children’s Hospital/
Leiden University Medical Center. All authors contributed to and approved
the final manuscript.
Acknowledgments
This study was financially supported by the Dutch Cancer Society and by the
Children Cancer Free Foundation.
The DCOG LATER-VEVO study group includes the following persons:
Beerendonk CCM (Radboud University Nijmegen Medical Center), van den
Berg MH (VU University Medical Center, Amsterdam), Bökkerink JP (Radboud
University Nijmegen Medical Center), van den Bos C (Emma Children’s
Hospital/Academic Medical Center, Amsterdam), Bresters D Leiden University
Medical Center), van Dorp W (Sophia Children’s Hospital/Erasmus MC
University Medical Center, Rotterdam), van Dulmen-den Broeder E (VU
University Medical Center, Amsterdam), van Engelen MP (Wilhelmina’s
Children’s Hospital, University Medical Center Utrecht), van den Heuvel-
Eibrink MM (Sophia Children’s Hospital/Erasmus MC University Medical
Center, Rotterdam), Huizinga GA (Beatrix Children’s Hospital/University
Medical Center Groningen), Jaspers MWM (Academic Medical Center-
University of Amsterdam), Kaspers GJL (VU University Medical Center,Amsterdam), Kremer LCM (Emma Children’s Hospital/Academic Medical
Center, Amsterdam), Lambalk CB (VU University Medical Center, Amsterdam),
Laven JS (Sophia Children’s Hospital/Erasmus MC University Medical Center,
Rotterdam), van Leeuwen FE (Netherlands Cancer Institute, Amsterdam),
Loonen JJ (Radboud University Nijmegen Medical Center), Louwerens M
(Leiden University Medical Center), Overbeek A (VU University Medical
Center, Amsterdam), van der Pal HJH (Emma Children’s Hospital/Academic
Medical Center, Amsterdam), Ronckers CM (DCOG LATER-Longterm Effects
after Childhood Cancer, The Hague), Simons AHM (University Medical Center
Groningen), Tissing WJE (Beatrix Children’s Hospital/University Medical Center
Groningen), Tonch N (Academic Medical Center, Amsterdam), Verkerk ECM
(DCOG LATER-Longterm Effects after Childhood Cancer, The Hague), and
Versluys AB (Wilhelmina’s Children’s Hospital, University Medical Center
Utrecht).
Author details
1Department of Paediatrics, Division of Paediatric Oncology/Haematology,
VU University Medical Center, PO Box 7057, Amsterdam 1007MB,
The Netherlands. 2Department of Obstetrics and Gynaecology, VU University
Medical Center, Amsterdam, The Netherlands. 3Department of Paediatric
Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam,
The Netherlands. 4Department of Pediatric Oncology, Sophia Children’s
Hospital/Erasmus MC University Medical Center, Rotterdam, The Netherlands.
5Department of Pediatric Oncology, Beatrix Children’s Hospital/University
Medical Center Groningen, Groningen, The Netherlands. 6Department of
Pediatric Oncology, Radboud University Nijmegen Medical Center, Nijmegen,
The Netherlands. 7Department of Pediatric Oncology, Wilhelmina’s Children’s
Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
8Department of Pediatric Stem Cell Transplantation, Willem-Alexander
Children’s Hospital, Leiden University Medical Center, Leiden, The
Netherlands. 9Department of Epidemiology, Netherlands Cancer Institute,
Amsterdam, The Netherlands.
Received: 18 July 2012 Accepted: 16 August 2012
Published: 23 August 2012
References
1. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y,
Robison LL, Sklar CA: Acute ovarian failure in the childhood cancer
survivor study. J Clin Endocrinol Metab 2006, 91:1723–1728.
2. Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y:
Ovarian failure and reproductive outcomes after childhood cancer
treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol
2009, 27:2374–2381.
3. Madanat-Harjuoja LM, Malila N, Lahteenmaki PM, Boice JD Jr, Gissler M, Dyba T:
Preterm delivery among female survivors of childhood, adolescent and
young adulthood cancer. Int J Cancer 2010, 127:1669–1679.
4. Reulen RC, Zeegers MP, Wallace WH, Frobisher C, Taylor AJ, Lancashire ER,
Winter DL, Hawkins MM: Pregnancy outcomes among adult survivors of
childhood cancer in the British Childhood Cancer Survivor Study. Cancer
Epidemiol Biomarkers Prev 2009, 18:2239–2247.
5. Signorello LB, Mulvihill JJ, Green DM, Munro HM, Stovall M, Weathers RE,
Mertens AC, Whitton JA, Robison LL, Boice JD Jr: Stillbirth and neonatal
death in relation to radiation exposure before conception: a
retrospective cohort study. Lancet 2010, 376:624–630.
6. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J,
Green D, Nicholson HS, Yasui Y, Robison LL: Premature menopause in
survivors of childhood cancer: a report from the childhood cancer
survivor study. J Natl Cancer Inst 2006, 98:890–896.
7. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP,
Hakvoort-Cammel FG, van den Bos C, van den Berg H, Pieters R, de Muinck
Keizer-Schrama SM: Anti-Mullerian hormone is a sensitive serum marker for
gonadal function in women treated for Hodgkin's lymphoma during
childhood. J Clin Endocrinol Metab 2007, 92:3869–3874.
8. Lie FS, van den Heuvel-Eibrink MM, Eijkemans MJ, Schipper I, Hukkelhoven
CW, Laven JS: Pregnancy outcome in female childhood cancer survivors.
Hum Reprod 2010, 25:1206–1212.
9. van Dorp W, van Beek RD, Laven JS, Pieters R, de Muinck Keizer-Schrama SM,
van den Heuvel-Eibrink MM: Long-term endocrine side effects of
childhood Hodgkin's lymphoma treatment: a review. Hum Reprod
Overbeek et al. BMC Cancer 2012, 12:363 Page 11 of 11
http://www.biomedcentral.com/1471-2407/12/363Update 2012, 18:12–28.
10. Armstrong GT, Whitton JA, Gajjar A, Kun LE, Chow EJ, Stovall M,
Leisenring W, Robison LL, Sklar CA: Abnormal timing of menarche in
survivors of central nervous system tumors: A report from the
Childhood Cancer Survivor Study. Cancer 2009, 115:2562–2570.
11. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, Holmes GF, Holmes
FF, Latourette HB, Meigs JW: Early menopause in long-term survivors of
cancer during adolescence. Am J Obstet Gynecol 1992, 166:788–793.
12. Chiarelli AM, Marrett LD, Darlington G: Early menopause and infertility in
females after treatment for childhood cancer diagnosed in 1964–1988
in Ontario, Canada. Am J Epidemiol 1999, 150:245–254.
13. Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB,
Pendergrass TW, Robison LL: Pregnancy outcome of female survivors of
childhood cancer: a report from the Childhood Cancer Survivor Study.
Am J Obstet Gynecol 2002, 187:1070–1080.
14. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC,
Donaldson SS, Byrne J, Robison LL: Fertility of female survivors of
childhood cancer: a report from the childhood cancer survivor study.
J Clin Oncol 2009, 27:2677–2685.
15. Magelssen H, Melve KK, Skjaerven R, Fossa SD: Parenthood probability and
pregnancy outcome in patients with a cancer diagnosis during
adolescence and young adulthood. Hum Reprod 2008, 23:178–186.
16. Mueller BA, Chow EJ, Kamineni A, Daling JR, Fraser A, Wiggins CL,
Mineau GP, Hamre MR, Severson RK, Drews-Botsch C: Pregnancy outcomes
in female childhood and adolescent cancer survivors: a linked cancer-
birth registry analysis. Arch Pediatr Adolesc Med 2009, 163:879–886.
17. Reinmuth S, Liebeskind AK, Wickmann L, Bockelbrink A, Keil T, Henze G,
Borgmann A: Having children after surviving cancer in childhood or
adolescence - results of a Berlin survey. Klin Padiatr 2008, 220:159–165.
18. Sudour H, Chastagner P, Claude L, Desandes E, Klein M, Carrie C, Bernier V:
Fertility and pregnancy outcome after abdominal irradiation that
included or excluded the pelvis in childhood tumor survivors. Int J Radiat
Oncol Biol Phys 2010, 76:867–873.
19. Winther JF, Boice JD Jr, Svendsen AL, Frederiksen K, Stovall M, Olsen JH:
Spontaneous abortion in a Danish population-based cohort of childhood
cancer survivors. J.Clin.Oncol 2008, 26:4340–4346.
20. Bath LE, Critchley HO, Chambers SE, Anderson RA, Kelnar CJ, Wallace WH:
Ovarian and uterine characteristics after total body irradiation in
childhood and adolescence: response to sex steroid replacement. Br J
Obstet Gynaecol 1999, 106:1265–1272.
21. Bath LE, Wallace WHB, Shaw MP, Fitzpatrick C, Anderson RA: Depletion of
ovarian reserve in young women after treatment for cancer in
childhood: Detection by anti-Mullerian hormone, inhibin B and ovarian
ultrasound. Hum Reprod 2003, 18:2368–2374.
22. Lantinga GM, Simons AH, Kamps WA, Postma A: Imminent ovarian failure
in childhood cancer survivors. Eur J Cancer 2006, 42:1415–1420.
23. Larsen EC, Muller J, Rechnitzer C, Schmiegelow K, Andersen AN: Diminished
ovarian reserve in female childhood cancer survivors with regular
menstrual cycles and basal FSH <10 IU/l. Hum Reprod 2003, 18:417–422.
24. Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN: Reduced
ovarian function in long-term survivors of radiation- and chemotherapy-
treated childhood cancer. J Clin Endocrinol Metab 2003, 88:5307–5314.
25. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH,
Sonneveld P, Laven JS: Anti-mullerian hormone as a marker of ovarian
function in women after chemotherapy and radiotherapy for
haematological malignancies. Hum Reprod 2008, 23:674–678.
26. Lie Fong S, Van Den Heuvel-Eibrink M: Pregnancy outcome in female
childhood cancer survivors. In Molecular Human Reproduction Conference:
25th Annual Meeting of the European Society of Human Reproduction and
Embryology, ESHRE. Amsterdam Netherlands: Conference Publication; 2009:
i101. Conference Start: 20090628 Conference End: 20090701.
27. Wallace WH, Thomson AB, Saran F, Kelsey TW: Predicting age of ovarian
failure after radiation to a field that includes the ovaries. Int J Radiat
Oncol Biol Phys 2005, 62:738–744.
28. de Boer EJ, Den Tonkelaar I, Burger CW, van Leeuwen FE: Validity of
self-reported causes of subfertility. Am J Epidemiol 2005, 161:978–986.
29. van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB,
Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ,
Willemsen WN, Smeenk JM, Simons AH, van der Veen F, Evers JL,
van Dop PA, Macklon NS, Burger CW: Risk of borderline and invasiveovarian tumours after ovarian stimulation for in vitro fertilization in a
large Dutch cohort. Hum Reprod 2011, 26:3456–3465.
30. Hoonakker P, Carayo P: Questionnaire Survey Nonresponse: A
Comparison of Postal Mail and Internet Surveys. Int J Hum Comput
Interact 2009, 25:348–373.
31. Pealer LN, Weiler RM, Pigg RM Jr, Miller D, Dorman SM: The feasibility of a
web-based surveillance system to collect health risk behavior data from
college students. Health Educ Behav 2001, 28:547–559.
32. Vereecken CA, Maes L: Comparison of a computer-administered and
paper-and-pencil-administered questionnaire on health and lifestyle
behaviors. J Adolesc Health 2006, 38:426–432.
33. van den Berg MH, Overbeek A, van der Pal HJ, Versluys AB, Bresters D,
van Leeuwen FE, Lambalk CB, Kaspers GJ, van Dulmen-den Broeder E: Using
web-based and paper-based questionnaires for collecting data on
fertility issues among female childhood cancer survivors: differences in
response characteristics. J Med Internet Res 2011, 13:e76.
34. Coolman M, de Groot CJ, Jaddoe VW, Hofman A, Raat H, Steegers EA:
Medical record validation of maternally reported history of
preeclampsia. J Clin Epidemiol 2010, 63:932–937.
35. Olson JE, Shu XO, Ross JA, Pendergrass T, Robison LL: Medical record validation
of maternally reported birth characteristics and pregnancy-related events: a
report from the Children's Cancer Group. Am J Epidemiol 1997, 145:58–67.
36. Rice F, Lewis A, Harold G, van den BM, Boivin J, Hay DF, Owen MJ, Thapar A:
Agreement between maternal report and antenatal records for a range
of pre and peri-natal factors: the influence of maternal and child
characteristics. Early Hum Dev 2007, 83:497–504.
37. Overbeek A, van den Berg MH, Hukkelhoven CWPM, Malhoe P, Kaspers GJ,
Lambalk CB, van Dulmen-den Broeder E, van Leeuwen FE. Validity of self-
reported data on pregnancies: a comparison of self-report with data
from a nationwide population-based registry. Accepted (11–10–2012)/ in
press Human Reproduction.
38. de Boer EJ, Den Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE:
Increased risk of early menopausal transition and natural menopause after
poor response at first IVF treatment. Hum Reprod 2003, 18:1544–1552.
39. Jayaprakasan K, Walker KF, Clewes JS, Johnson IR, Raine-Fenning NJ: The
interobserver reliability of off-line antral follicle counts made from stored
three-dimensional ultrasound data: a comparative study of different
measurement techniques. Ultrasound Obstet Gynecol 2007, 29:335–341.
40. Jayaprakasan K, Campbell BK, Clewes JS, Johnson IR, Raine-Fenning NJ:
Three-dimensional ultrasound improves the interobserver reliability of
antral follicle counts and facilitates increased clinical work flow.
Ultrasound Obstet Gynecol 2008, 31:439–444.
41. Merce LT, Gomez B, Engels V, Bau S, Bajo JM: Intraobserver and interobserver
reproducibility of ovarian volume, antral follicle count, and vascularity
indices obtained with transvaginal 3-dimensional ultrasonography, power
Doppler angiography, and the virtual organ computer-aided analysis
imaging program. J Ultrasound Med 2005, 24:1279–1287.
42. Scheffer GJ, Broekmans FJ, Bancsi LF, Habbema JD, Looman CW, te Velde ER:
Quantitative transvaginal two- and three-dimensional sonography of the
ovaries: reproducibility of antral follicle counts. Ultrasound Obstet Gynecol
2002, 20:270–275.
43. Ness KK, Leisenring W, Goodman P, Kawashima T, Mertens AC, Oeffinger KC,
Armstrong GT, Robison LL: Assessment of selection bias in clinic-based
populations of childhood cancer survivors: a report from the childhood
cancer survivor study. Pediatr Blood Cancer 2009, 52:379–386.
doi:10.1186/1471-2407-12-363
Cite this article as: Overbeek et al.: A nationwide study on reproductive
function, ovarian reserve, and risk of premature menopause in female
survivors of childhood cancer: design and methodological challenges.
BMC Cancer 2012 12:363.
